Abbott's lower-strength pediatric tablet formulation of the HIV protease inhibitor Kaletra has received marketing approval by the European Commission.
Abbott's lower-strength pediatric tablet formulation of the HIV protease inhibitor Kaletra has received marketing approval by the European Commission.
Kaletra is indicated for the treatment of HIV-1 infected adults and children over the age of 2, and is used in combination with other antiretroviral agents. The lower-strength tablet improves dosing convenience for HIV-positive children without compromising efficacy.
For example, Kaletra's soft gel capsule formulation required accompanying food intake, while the oral solution needed refrigeration. The new version requires neither food intake nor refrigeration, and contains lower doses of the active ingredient than the adult formulation.
How culinary knowledge can impact physical, mental and environmental health
October 22nd 2023In this Contemporary Pediatrics interview, Michelle Loy, MD, FAAP, recaps her session, "Culinary Medicine: Using Food for Physical, Mental, and Environmental Health" presented at the 2023 American Academy of Pediatrics National Conference & Exhibition in Washington DC.
How do infant formulas compare to composition or performance of human milk?
June 14th 2023Infant formula companies add new ingredients to match or best mimic human milk and breastfeeding advantage for the child, but comparing new-ingredient formulas with existing formulas and human milk to determine efficaciousness can present clinical and ethical challenges.